Szarkóma: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• KRAS 10
• TP53 1
• PD-1 19
• PD-L1 9
• PI3K 0
• AKT 0
• NTRK 2
• mTOR 0
• STAT3 0
• MAPK 0
• CTNNB1 0
• MDM2 2
• BRAF 3
• MYC 0
• RAS 3
• ERK 0
• JNK 0
• VEGF 3
• ALK 2
• B7-H3 10
• STING 1
• CDK4/6 3
• EGFR 1
• JAK 1
• PARP 4
• YAP 0
• IDH 2
• FGFR 2
• HER2 5
• MEK 2
• CTLA-4 5
• NRAS 0
• GPX4 0
• HIF-1 0
• PTEN 0
• EZH2 0
• PPAR 0
• METTL3 1
• NF1 5
• AMPK 0
• GPC3 5
• PDGFR 3
• ABL1 0
• CD47 0
• COX-2 0
• ROS1 2
• AXL 0
• CDKN2A 0
• CXCR4 0
• IL-15 4
• MMP-9 0
• PRAME 1
• PSMA 0
• RET 0
• BCL-2 0
• BRCA2 1
• CD19 2
• FLT3 0
• FTO 0
• HDAC 0

17+ intézményből 17, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• FDA · U01

  Disulfiram/Copper as a Dual Senolytic Strategy Targeting Tumor and Immune Cell Senescence in Chordoma

  Massachusetts General Hospital· Boston, Egyesült Államok· 1 000 000 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIA · R01

  Synapse repair in Alzheimer's disease and related dementias

  Buck Institute for Research on Aging· Novato, Egyesült Államok· 785 081 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NINDS · R43

  Development of an Anti-Nerve Growth Factor Active Immunotherapy for Difficult-to-Manage Pain

  Twilight Bioscience, Inc.· Topsfield, Egyesült Államok· 350 188 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIAMS · R21

  Failure to resolve an adaptive stress state contributes to Duchenne Muscular Dystrophy Severity

  University of Southern California· Los Angeles, Egyesült Államok· 211 650 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NCI · R43

  Preclinical development of novel dual EZH2-BRD4 inhibitor for EZH2-mutant lymphoma

  Biologica Llc· Charlotte, Egyesült Államok· 385 056 USD awarded in fiscal year 2026· until 2027. aug.

• European Commission (Horizon Europe) · HORIZON-ERC

  Primary bone cancer scaffolds as controlled release non-viral gene delivery platforms (PANACEA)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 2 302 626 EUR· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Self-Assembling, Self-Monitoring, Multi-Stimuli-Responsive Implants for the Minimally Invasive Treatment of Critical-Size Defects (Morphogenesis)

  Fundacion Imdea Materiales· Getafe, Spanyolország· EU contribution 194 075 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of RNA-binding proteins in telomere replication stress and alternative lengthening of telomeres (RBPandALT)

  The Francis Crick Institute Limited· London, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Predicting single-cell ploidy from digital pathology images in pan-sarcoma (SImPloidy)

  University College London· London, Egyesült Királyság· EU contribution 276 188 EUR· until 2027. máj.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-IA

  Sustainable 4D hydrogels functionalised with plant-based nanoparticles for bone regeneration in cancer patients (GreenNanoBone)

  The University of Liverpool· Liverpool, Egyesült Királyság· EU contribution 8 649 982 EUR· until 2029. máj.· 12 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 473 running projects, newest first. Listed amounts together: 249,7 M USD + 53,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Leállított, visszavont és felfüggesztett vizsgálatok, a szponzor által a regiszterben megadott okkal, szó szerint idézve.

• Leállították

  Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma

  NCT03116529· University of Maryland, Baltimore· Frissítve: 2026. nov. 5.

  “Limited Accrual”A regiszter szövege, változtatás nélkül. Forrás

• Felfüggesztve

  Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or Metastatic NSCLC

  NCT07639242· UNC Lineberger Comprehensive Cancer Center· Frissítve: 2026. aug. 28.

  “Administrative”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

  NCT04260802· Ocellaris Pharma, Inc.· Frissítve: 2026. jan. 12.

  “Business Decision”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

  NCT02936102· Novartis Pharmaceuticals· Frissítve: 2025. nov. 14.

  “The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.”A regiszter szövege, változtatás nélkül. Forrás

• Leállították

  Study on TSR-042 in Advanced Clear Cell Sarcoma

  NCT04274023· Italian Sarcoma Group· Frissítve: 2024. febr. 1.

  “Difficulty of enrollment”A regiszter szövege, változtatás nélkül. Forrás

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Merck Sharp & Dohme LLC· Forrás

• KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

  NCT07252739· Merck Sharp & Dohme LLC· Forrás

• A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  NCT06066138· National Cancer Institute (NCI)· Forrás

• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

  NCT06008093· AstraZeneca· Forrás

• Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

  NCT04902443· National Cancer Institute (NCI)· Forrás

• Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

  NCT04458922· National Cancer Institute (NCI)· Forrás

• Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

  NCT04242238· Memorial Sloan Kettering Cancer Center· Forrás

• A phase II study to assess the efficacy of the anti-PD-L1 antibody atezolizumab (MPDL3280A) administered with stereotactic ablative radiotherapy (SABR) in patients with metastatic tumours (SABR-PDL1)

  2024-515678-29-00· Institut Gustave Roussy· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 41
• Organoids 10
• Mendelian Randomization Analysis 2
• CRISPR-Cas Systems 11
• Gene Expression Profiling 99
• Sequence Analysis, RNA 21
• Whole Genome Sequencing 4
• Exome Sequencing 14
• Proteomics 31
• Metabolomics 7
• Mass Spectrometry 5
• Flow Cytometry 52
• Immunohistochemistry 186
• Liquid Biopsy 12
• Circulating Tumor DNA 19
• Xenograft Model Antitumor Assays 152
• Positron-Emission Tomography 19
• Magnetic Resonance Imaging 197
• Machine Learning 28
• Deep Learning 16
• Cohort Studies 30
• Genome-Wide Association Study 2

• Leveraging Single-Cell RNA Sequencing to Characterize Murine Ewing Sarcoma Xenografts.

  Methods Mol Biol, 2027. jan.

• Multimodal single-cell analyses reveal distinct fusion-regulated transcriptional programs in Ewing sarcoma.

  Elife, 2026. nov.

• High-Risk Rhabdomyosarcomas Feature a Convergent Cell State.

  Cancer Res, 2026. okt.

• Integrative Bulk, Single-Cell, and Spatial Transcriptomic Analyses Nominate PPARG as a Candidate Senescence-Related Prognostic Gene in Osteosarcoma.

  J Vis Exp, 2026. szept.

• Single-cell mapping of chromosome breaks identifies multiple fragile site classes with distinct DNA replication timing landscapes.

  Nat Commun, 2026. szept.

• Integrative single-cell and bulk transcriptomics uncovers a lipid metabolism-related lncRNA signature alongside the ELFN1-AS1/LYPLA1 axis driving osteosarcoma progression.

  Front Immunol, 2026. szept.

• Single-cell transcriptomic analysis reveals fatty acid metabolic heterogeneity and identifies DKK1 as a candidate prognostic factor in osteosarcoma.

  Front Endocrinol (Lausanne), 2026. szept.

• scGPA: an LLM-assisted workflow for directional virtual gene perturbation analysis from single-cell transcriptomes.

  BMC Genomics, 2026. aug.

• Single-cell multi-omics reveals NUF2 as a potential biomarker associated with the high-lactylation malignant state in osteosarcoma.

  Int J Biol Markers, 2026. aug.

• Single-cell analysis reveals the potential immunoregulatory role of C3 + malignant cell subpopulations in dedifferentiated liposarcoma.

  BMC Cancer, 2026. aug.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.